Skin Lightening Compositions
AssigneeELC Management LLC
InventorsYoko Niki, Masakj Yoshida, Masamitsu Ichihashi, Hideya Ando, Daniel B. Yarosh, Mary S. Matsui
Life of this patent
Estimating the term…
Abstract
Compositions and methods for lightening and/or depigmenting skin are provided, the compositions comprising compounds having the structure: or having the structure: as defined herein.
Claims10
A topically applicable composition for lightening or depigmenting skin, comprising a skin lightening or depigmenting effective amount of at least one compound represented by the structural formula:
- wherein:
- R2 is hydrogen, lower alkyl or hydroxy lower alkyl;
- R3 is lower alkyl, —CH2CN, hydroxy lower alkyl, —NO, —CH2N═C or
- (wherein R6 and R7 are independently selected from the group consisting of hydrogen and lower alkyl) or hydrogen provided R2 is not hydrogen;
- R4 is Z-T-W wherein Z represents —O—, —NH— or a single bond;
- T represents a straight- or branched-chain lower-alkylene group;
- when Z is a single bond, T also represents an ethenylene or a propenylene group wherein the unsaturated carbon is at the single bond;
- when Z is —O—, T also represents an allylene group wherein the saturated carbon is at the oxygen;
- and W represents hydrogen, when T is allylene and Z is —O—, or Ar, wherein Ar is selected from thienyl, pyridinyl, furanyl, phenyl and substituted phenyl wherein there are one or more substituents on the phenyl independently selected from halogen or lower alkyl;
- and
- R5 is hydrogen, halogen or lower alkyl;
- or
- SCH32651 (3-amino-2-methyl-8-phenylmethoxyimidazo[1,2-a]pyrazine;
- or a derivative or physiologically acceptable salt, solvate or bioprecursor, or any stereoisomer or enantiomer thereof;
- formulated into a topically applicable, cosmetically or dermatologically acceptable vehicle, carrier or diluent therefor.
A topically applicable composition for lightening or depigmenting skin, comprising a skin lightening or depigmenting effective amount of at least one compound selected from the group consisting of SCH 28080 (3-(cyanomethyl)-2-methyl-8-phenylmethoxy-imidazo[1,2-a]pyridine);
- SCH 32651 (3-amino-2-methyl-8-phenylmethoxyimidazo[1,2-a]pyrazine) soraprazan ([(7R,8R,9R)-2,3-dimethyl-8-hydroxy-7(2-methoxyethoxy)-9-phenyl-7,8,9,10-tetrahydro-imidazo-[1,2-h][1,7]-naphthyridine]);
- pumaprazole (8-(2-methoxycarbonylamino-6-benzulamino)-2,3-dimethylimidazo-[1,2-a)pyridine-D,L-hemimalate];
- AR-H047108 ((8-[(2-ethyl-6-methylbenzyl)amino]2,3-dimethylimidazo[1,2-a]pyridine-6-carboxamide);
- dapiprazole (3-{2-[4-(2-methylphenyl)piperazin-1-yl]ethyl}-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,5-a]pyridine);
- AZD0865 ((8-[2,6-dimethylbenzyl)amino]-N-(2-hydroxyethyl)-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxamide);
- tenatoprazole (3-methoxy-8-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methylsulfinyl]-2,7,9-triazabicyclo[4.3.0]nona-2,4,8,10-tetraene);
- aripiprazole (7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one);
- revaprazan ([5,6-dimethyl-2-(4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl-pyrimidine]);
- and CS-526 (7-(4-fluorobenzyloxy)-2,3-dimethyl-1-{[(1S,2S)-2-methylcyclopropyl]methyl}-1H-pyrrolo[2,3-d]pyridazine), formulated into a topically applicable, cosmetically or dermatologically acceptable vehicle, carrier or diluent therefor.
Dependencies are inferred from the claim text.